The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Anti-influenza antibody compositions. Buy the report here.

Smarter leaders trust GlobalData

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

110 innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

Anti-influenza antibody compositions is a key innovation area in pharmaceuticals

Influenza viruses are members of the family orthomyxoviridae. There are four types of influenza viruses: A, B, C, and D. Hemagglutinin (HA), an envelope glycoprotein on the influenza virion enables the virus to enter and spread between cells. This protein also serves as a target for neutralizing antibodies, which can be used to develop for therapeutic as well as diagnostic applications.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 210+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of anti-influenza antibody compositions.

Key players in anti-influenza antibody compositions – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to anti-influenza antibody compositions

Company Total patents (2010 - 2022) Premium intelligence on the world's largest companies
GSK 853 Unlock Company Profile
Johnson & Johnson 706 Unlock Company Profile
Mitsubishi Chemical Group 391 Unlock Company Profile
C. H. Boehringer Sohn 387 Unlock Company Profile
CSL 256 Unlock Company Profile
Novavax 248 Unlock Company Profile
Sanofi 247 Unlock Company Profile
Curevac 148 Unlock Company Profile
Merck & Co 125 Unlock Company Profile
Moderna 119 Unlock Company Profile
Altimmune 114 Unlock Company Profile
Takeda Pharmaceutical 109 Unlock Company Profile
Selecta Biosciences 106 Unlock Company Profile
Pfizer 103 Unlock Company Profile
Academia Sinica 95 Unlock Company Profile
Zoetis 87 Unlock Company Profile
Vir Biotechnology 85 Unlock Company Profile
FluGen 83 Unlock Company Profile
Temasek Life Sciences Laboratory 77 Unlock Company Profile
Theraclone Sciences 76 Unlock Company Profile
Nitto Denko 71 Unlock Company Profile
Celltrion 70 Unlock Company Profile
Baxter International 69 Unlock Company Profile
Eli Lilly and 66 Unlock Company Profile
SEEK Group 61 Unlock Company Profile
FDS Pharma LLP 61 Unlock Company Profile
SK Chemicals 59 Unlock Company Profile
United States Of America 58 Unlock Company Profile
IMV 58 Unlock Company Profile
Vaxart 55 Unlock Company Profile
Viridos 55 Unlock Company Profile
Valneva 54 Unlock Company Profile
3M 53 Unlock Company Profile
Meiji Holdings 49 Unlock Company Profile
Bavarian Nordic 48 Unlock Company Profile
Solon Eiendom 48 Unlock Company Profile
Eurocine Vaccines 46 Unlock Company Profile
St. Jude Children’s Research Hospital 45 Unlock Company Profile
Otsuka Holdings 45 Unlock Company Profile
National Resilience 45 Unlock Company Profile
BiondVax Pharmaceuticals 43 Unlock Company Profile
Autoimmune Technologies 42 Unlock Company Profile
European Molecular Biology Laboratory 42 Unlock Company Profile
Inovio Pharmaceuticals 42 Unlock Company Profile
US Department of Health and Human Services 41 Unlock Company Profile
Abbott Laboratories 39 Unlock Company Profile
Novartis 38 Unlock Company Profile
Toko Pharmaceutical Industries 36 Unlock Company Profile
Catalent 35 Unlock Company Profile
Utilities Service Alliance 34 Unlock Company Profile

Source: GlobalData Patent Analytics

GSK is the leading patent filer for anti-influenza antibody compositions. It offers drugs spanning therapeutic areas such as respiratory, oncology, immuno-inflammation, central nervous system (CNS), metabolic, cardiovascular, dermatology, bacterial infections, viral infections, including HIV, and rare diseases.  GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus, influenza and HPV infections, measles, and bacterial meningitis, among others.

In terms of application diversity, HLB Science is the top company, followed by Cidara Therapeutics and BravoVax. By means of geographic reach, Selecta Biosciences holds the top position. While Toko Pharmaceutical Industrial and Catalent are in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.